ライフサイエンスコーパス: lymph node biopsy

1 potentially more sensitive than conventional lymph node biopsy).

2 is established by serological methods and/or lymph node biopsy.

3 osis is established by serologic methods and lymph node biopsy.

4 efficacy of axillary dissection and sentinel lymph node biopsy.

5 LND in the primary setting or after sentinel lymph node biopsy.

6 LND in the primary setting or after sentinel lymph node biopsy.

7 d decreased false-negative rates in sentinel lymph node biopsy.

8 ve and avoid unnecessary and costly axillary lymph node biopsy.

9 a partial mastectomy with axillary sentinal lymph node biopsy.

10 He underwent an excisional lymph node biopsy.

11 mpectomy with seed localization and sentinel lymph node biopsy.

12 biopsy, and partial mastectomy with sentinel lymph node biopsy.

13 tinal lymphoma was followed by DLBCL after a lymph node biopsy.

14 vant radiotherapy and the timing of sentinel lymph node biopsy.

15 ery, the patient had undergone a mediastinal lymph node biopsy.

16 houlder than patients who underwent sentinel-lymph-node biopsy.

17 Ci dose of I methylene blue dye for sentinel lymph node biopsies.

18 tein expression in CD4 T cells obtained from lymph node biopsies.

19 s were identified on laparoscopic mesenteric lymph nodes biopsies.

20 75 (74%) had no axillary biopsy or sentinel lymph node biopsy; 26 (26%) had undergone ALND; and 38 (

21 ft-tissue abscess procedures 48% (34/71) and lymph node biopsies 67% (10/15) (P < 0.01) were most oft

22 We found that in fresh Hodgkin's disease lymph node biopsies, a subset of HRS cells express a sub

23 er EBV-infected B-cell line, isolated from a lymph node biopsy after kidney transplantation, is pheno

24 axillary staging was noninferior to sentinel-lymph-node biopsy after a median follow-up of 6 years.

25 nt chemotherapy could safely permit sentinel lymph node biopsy alone when the index node has been suc

26 biopsy plus axillary dissection or sentinel-lymph-node biopsy alone.

27 alignant lymphocytes and lymphoma cells from lymph node biopsies and were expressed at significant le

28 eons in a standardized technique of sentinel lymph node biopsy and to educate those same surgeons in

29 examination and, where appropriate, sentinel lymph node biopsy) and can include surgery, checkpoint i

30 nts underwent lymphatic mapping and sentinel lymph node biopsy, and 10 had a positive axillary lymph

31 One patient had a sentinel lymph node biopsy, and 8 patients underwent head/neck im

32 t intraoperative lymphatic mapping, sentinel lymph node biopsy, and inguinal femoral lymphadenectomy.

33 lder underwent wide local excision, sentinel lymph node biopsy, and lymph node dissection.

34 repair, partial mastectomy without sentinel lymph node biopsy, and partial mastectomy with sentinel

35 burden, deselection of patients for sentinel lymph node biopsy, and provision of radiotherapy.

36 (T4b) cutaneous melanoma; negative sentinel lymph node biopsy; and an Eastern Cooperative Oncology G

37 plications for the potential use of sentinel lymph node biopsy as an alternative to axillary dissecti

38 erum samples) diagnosed serologically and by lymph node biopsy as having TL were studied.

39 Available evidence for the role of sentinel lymph node biopsy as it applies to conjunctival melanoma

40 tudied highly purified CD4 and CD8 TILs from lymph node biopsies at diagnosis in treatment-naive pati

41 to select appropriate patients for sentinel lymph node biopsy based on multiple prognostic factors,

42 notherapy (3600 or 7200 mg/day) underwent 14 lymph node biopsies before and during therapy.

43 when selecting patients to undergo sentinel lymph node biopsy but did not reach consensus on imaging

44 the indications and techniques for sentinel-lymph-node biopsy, but also lymph-node sampling, axillar

45 Sentinel lymph node biopsy can be associated with delays in opera

46 Sentinel lymph node biopsy can be considered in select tumors and

47 Sentinel lymph node biopsy can be performed either before or afte

48 inical trials will evaluate whether sentinel-lymph-node biopsy can be avoided altogether in selected

49 Here, we analyzed tumor-containing lymph node biopsies collected from these patients.

50 and activation status of Tfh and B cells in lymph node biopsies collected in the different stages of

51 All patients underwent sentinel lymph node biopsy; completion lymphadenectomy was perfor

52 lysis and histological examination of serial lymph node biopsies confirmed depletion of the CD3+ T ce

53 ormalities, and the findings of a subsequent lymph node biopsy confirmed MCD.

54 h an increased number of Ki-67(+) T cells in lymph node biopsies, consistent with an early antiviral

55 bidity and diagnostic delays associated with lymph node biopsy could be avoided if noninvasive imagin

56 Sentinel lymph node biopsy does not appear to have a significant

57 propriate selection of patients for sentinel lymph node biopsy, especially among patients with thin m

58 is review highlights the utility of sentinel lymph node biopsy for melanoma.

59 nts who underwent thyroidectomy and sentinel lymph node biopsy for papillary thyroid cancer were accr

60 Two patients underwent sequential lymph-node biopsies for the assessment of viral burden i

61 or staging has now been replaced by sentinel-lymph-node biopsy for patients with clinically negative

62 Digital images of sentinel lymph node biopsies from 56 patients with small-volume n

63 ocked assay was applied to pretreatment FFPE lymph node biopsies from an independent cohort of 110 pa

64 Lymph node biopsies from early (2-5 h) and late (19-20 h

65 a variety of sources used as controls, nor 3 lymph node biopsies from patients with B-cell lymphomas,

66 DCs in lymph-node biopsies from the same patients showed a diff

67 clinical lymphedema: 8 (8%) in the sentinel lymph node biopsy group and 7 (37%) in the axillary lymp

68 approach to patients with positive sentinel lymph node biopsies has increased the complexity of axil

69 Sentinel-lymph-node biopsy has been embraced as a standard of car

70 The introduction of sentinel-lymph-node biopsy has brought new impetus to the early s

71 Sentinel-lymph-node biopsy has spread so rapidly that surgeons, p

72 udies in the past 2 years regarding sentinel lymph node biopsy have been concerned with identifying f

73 Lymphatic mapping and sentinel lymph node biopsy have been established as definitive pr

74 uggested that these new methods for sentinel lymph node biopsy have clinical potential but give high

75 Although details of methods for sentinel lymph node biopsy have yet to be standardised, this tech

76 decision about whether to perform a sentinel lymph node biopsy in 16% of patients (67 of 420 patients

77 y avoid invasive procedures such as sentinel lymph node biopsy in 68.2% of the patients.

78 r of surgeons capable of performing sentinel lymph node biopsy in a standardized fashion with a high

79 lateral prophylactic mastectomy and sentinel lymph node biopsy in older women increased during the st

80 ASCO 2017 guideline for the use of sentinel lymph node biopsy in patients with early-stage breast ca

81 e efficacy of lymphatic mapping and sentinel lymph node biopsy in predicting prognosis, reducing the

82 ic spread undermines the utility of sentinel lymph node biopsy in this condition.

83 f axillary surgery as compared with sentinel-lymph-node biopsy in patients with clinically node-negat

84 It is now well established that sentinel lymph node biopsy is a powerful test to predict prognosi

85 Sentinel lymph node biopsy is a promising procedure in patients w

86 Sentinel lymph node biopsy is a reasonable alternative to inguina

87 An excisional lymph node biopsy is considered the gold standard for di

88 Lymph node biopsy is employed in many cancer surgeries t

89 Sentinel lymph node biopsy is performed as a standard procedure i

90 Sentinel lymph node biopsy is recommended for cutaneous melanoma

91 Sentinel-lymph-node biopsy is associated with increased melanoma-

92 specific PCR identified the same mutation in lymph node biopsy material from patient CEM cells.

93 Absence of lymph node biopsy may result in understaging and inadequ

94 Novel techniques, such as sentinel lymph node biopsy, may allow for greater use of stomach-

95 d resistance mutations in blood and inguinal lymph node biopsies obtained from 10 HIV-infected subjec

96 istence and HIV-specific T cell responses in lymph node biopsies obtained from 14 individuals who ini

97 precisely BCL2-IGH translocations present in lymph node biopsies of follicular lymphoma patents.

98 s, it seems reasonable to recommend sentinel lymph node biopsy or at least strict regional lymph node

99 e, it may be reasonable to consider sentinel lymph node biopsy or close nodal surveillance and follow

100 erefore be reasonable to consider a sentinel lymph node biopsy or strict regional lymph node surveill

101 es, such as intraoperative imaging, sentinel lymph-node biopsy or the use of artificial intelligence,

102 with histologic findings from bone marrow or lymph node biopsy performed within 6 wk of PET/CT and wi

103 ssigned women with breast cancer to sentinel-lymph-node biopsy plus axillary dissection or sentinel-l

104 ctomy (PM), partial mastectomy with sentinel lymph node biopsy (PM SLNB), laparoscopic cholecystectom

105 mally invasive surgical staging and sentinel-lymph-node biopsy provides a low morbidity alternative t

106 ymph-node dissection, the role of 'sentinel' lymph-node biopsy, radiobiology and radiotherapy fractio

107 my rates ranged from 9% to 67%, and sentinel lymph node biopsy rates ranged from 25% to 97%.

108 characteristics, trends in usage of sentinel lymph node biopsy, rates of local and distant recurrence

109 Exercise and physical activity and sentinel lymph node biopsy reduce risk, and overweight and obesit

110 techniques could potentially render sentinel lymph node biopsy redundant in the future.

111 re than 40% of neck dissections and sentinel lymph node biopsies, respectively.

112 of melanoma (16%) after a negative sentinel lymph node biopsy result was similar to that in previous

113 k of recurrence, despite a negative sentinel lymph node biopsy result.

114 In two cases, lymph node biopsy results confirmed vaccination-related

115 served, CAR T cells were readily detected in lymph node biopsy samples from sites of original disease

116 We analyzed 46 fresh lymph node biopsy samples, including FL (n = 20), diffus

117 Lymph-node biopsy samples showed that focal lymphadeniti

118 Sentinel lymph node biopsy (SLN) is an accepted alternative to ax

119 There was a higher proportion of sentinel lymph node biopsies (SLNB) performed by high-volume surg

120 Observations: Sentinel lymph node biopsy (SLNB) after NAC in patients presentin

121 ode assessment (ALNA) consisting of sentinel lymph node biopsy (SLNB) alone if sentinel lymph nodes (

122 rding to axillary surgery approach: sentinel lymph node biopsy (SLNB) alone, SLNB+RLNR, axillary lymp

123 concerting lymphedema rates in both sentinel lymph node biopsy (SLNB) and axillary lymph node dissect

124 TAD involves TLN biopsy (TLNB) and sentinel lymph node biopsy (SLNB) and was recently introduced as

125 stectomy with axillary staging with sentinel lymph node biopsy (SLNB) and/or ALND and had 1 to 2 posi

126 ents with melanoma are selected for sentinel lymph node biopsy (SLNB) based on their risk of a positi

127 Whether sentinel lymph node biopsy (SLNB) can replace lymphadenectomy for

128 edure, was performed and after NAC, sentinel lymph node biopsy (SLNB) combined with excision of the m

129 aphy is standardly performed before sentinel lymph node biopsy (SLNB) for breast cancer.

130 Guidelines recommend sentinel lymph node biopsy (SLNB) for patients with clinical stag

131 The validity of sentinel lymph node biopsy (SLNB) for T1 or T2, clinically N0, or

132 Indications for sentinel lymph node biopsy (SLNB) for thin melanoma are continual

133 the sensitivity and specificity of sentinel lymph node biopsy (SLNB) frozen section (FS) examination

134 Sentinel lymph node biopsy (SLNB) has become the gold standard fo

135 entification of nodal metastases by sentinel lymph node biopsy (SLNB) has been questioned.

136 ical setting for the application of sentinel lymph node biopsy (SLNB) in the management of cutaneous

137 recommended against routine use of sentinel lymph node biopsy (SLNB) in this population; however, re

138 Sentinel lymph node biopsy (SLNB) is a newly developed method of

139 Although sentinel lymph node biopsy (SLNB) is a vital staging tool, its ap

140 Sentinel lymph node biopsy (SLNB) is an accurate, less invasive a

141 Sentinel lymph node biopsy (SLNB) is an important technique in th

142 Sentinel lymph node biopsy (SLNB) is being evaluated in breast ca

143 inically localized T1 melanoma, yet sentinel lymph node biopsy (SLNB) is controversial in this popula

144 Sentinel lymph node biopsy (SLNB) is currently the standard of ca

145 Sentinel lymph node biopsy (SLNB) is the standard of care for axi

146 Sentinel lymph node biopsy (SLNB) is the standard of care for axi

147 Existing studies suggest that sentinel lymph node biopsy (SLNB) may not be reliable in IBC.

148 men 18 years or older who underwent sentinel lymph node biopsy (SLNB) or axillary lymph node dissecti

149 800 sec/mm(2)), followed by either sentinel lymph node biopsy (SLNB) or axillary lymph node dissecti

150 nal lymph node evaluation by either sentinel lymph node biopsy (SLNB) or complete lymph node dissecti

151 th cT1-4N1-3M0 disease treated with sentinel lymph node biopsy (SLNB) or targeted axillary dissection

152 erforming risk prediction model for sentinel lymph node biopsy (SLNB) positivity in melanoma.

153 ith lower- and higher-than-expected sentinel lymph node biopsy (SLNB) positivity rates and whether ho

154 Whether sentinel lymph node biopsy (SLNB) should be performed in patients

155 It has been validated that sentinel lymph node biopsy (SLNB) shows whether a patient's breas

156 nce rates of patients who underwent sentinel lymph node biopsy (SLNB) using radiocolloid guidance alo

157 Sentinel lymph node biopsy (SLNB) was developed to replace axilla

158 axillary evaluation, categorized as sentinel lymph node biopsy (SLNB), axillary lymph node dissection

159 pediatric melanoma database, using sentinel lymph node biopsy (SLNB), from 1992 to 2006, identified

160 l less invasive procedures, such as sentinel lymph node biopsy (SLNB), marking axillary lymph node wi

161 , including wide local excision and sentinel lymph node biopsy (SLNB), should follow National Compreh

162 biopsy results underwent subsequent sentinel lymph node biopsy (SLNB), which yielded negative finding

163 bservation and among subgroups with sentinel lymph node biopsy (SLNB)-negative and SLNB-positive find

164 n (ALND) but can also develop after sentinel lymph node biopsy (SLNB).

165 (LSG) enhances staging accuracy of sentinel lymph node biopsy (SLNB).

166 Final pathologic results (sentinel lymph node biopsy [SNB] or axillary lymph node dissectio

167 ences from a Bouin's-fixed paraffin-embedded lymph node biopsy specimen obtained in 1960 from an adul

168 cases), bone marrows (149 cases), and fresh lymph node biopsy specimens (68 cases).

169 4(+) cells was also confirmed by analysis of lymph node biopsy specimens 5 days postchallenge.

170 after the second protein boost, we obtained lymph node biopsy specimens and quantified the frequency

171 al RNA or DNA could be detected in colon and lymph node biopsy specimens collected 13 months after ch

172 We analyzed GC size and shape in excisional lymph node biopsy specimens from 14 patients with CVID+A

173 oarrays to profile gene expression in serial lymph node biopsy specimens obtained before and after tr

174 xpression of SIV Gag was readily detected in lymph node biopsy specimens taken at 3 weeks postimmuniz

175 ivity of adjuvant immunotherapy, is sentinel lymph node biopsy still needed in melanoma?

176 With the advent of sentinel lymph node biopsy, surgical methods for accurately stagi

177 Most treatments, including sentinel lymph node biopsy, systemic therapy with taxanes, platin

178 microarrays of paraffin-embedded, diagnostic lymph node biopsies taken from 59 FL patients who lived

179 unique cross-sectional analysis of inguinal lymph node biopsies taken prior to antiretroviral therap

180 Refinement of the sentinel-lymph-node biopsy technique might overcome the slightly

181 view to assess three techniques for sentinel lymph node biopsy that are not radioisotope dependent or

182 mission group), and 3896 to undergo sentinel-lymph-node biopsy (the surgery group).

183 With the advent of sentinel lymph node biopsy, the axilla can be accurately staged i

184 In patients undergoing sentinel lymph node biopsy, the ipsilateral axilla was imaged wit

185 mmunohistochemical analyses of tissue from a lymph node biopsy; the tissue morphology and antigen exp

186 C), but cultures of BAL fluid and subcarinal lymph node biopsy tissue were negative.

187 ively, in concert with pre- and on-treatment lymph node biopsies to assess retinoblastoma protein (Rb

188 ments and novel neck dissection and sentinel lymph node biopsy trays.

189 Sentinel lymph node biopsy use and 5-year cumulative incidence of

190 spective, multicenter cohort study (Sentinel Lymph Node Biopsy vs Lymphadenectomy for Intermediate- a

191 Sentinel lymph node biopsy was a possible option for 9/22 (41%) a

192 Sentinel lymph node biopsy was adopted for the staging of the axi

193 The absence of lymph node biopsy was also associated with an increased

194 Lymph node biopsy was performed from 60 dogs with B-cell

195 A sentinel lymph node biopsy was performed in 23.3% of the older pa

196 Sentinel lymph node biopsy was performed in 73.7% of white patien

197 Sentinel lymph node biopsy was performed using an increased (99m)

198 Lymph node biopsies were done in two of these three pati

199 ough January 1997, 35 sonographically guided lymph node biopsies were performed in 34 patients.

200 Five hundred consecutive sentinel lymph node biopsies were performed using isosulfan blue

201 patients in whom the diagnosis was based on lymph node biopsy were considered (P =.01).

202 TNM stage T3b or T4 with a negative sentinel lymph node biopsy) were recruited.

203 women with invasive carcinoma and a positive lymph node biopsy when compared to those with in-situ ca

204 ty-six participants (83%) underwent sentinel lymph node biopsy, whereas 14 (12%) underwent axillary l

205 Sentinel lymph node biopsy will not identify metastases in 3% of

206 From 1992 to 2000, we identified 23 lymph node biopsies with focal germinal centers (GCs) co

207 and radiologically normal axilla is sentinel lymph node biopsy with a radioisotope and blue dye (dual

208 ture DC were significantly reduced in day +5 lymph node biopsies, with complete repopulation by 30 da

209 noma in an era of increasing use of sentinel lymph node biopsy without CLND and should be considered